London, December 12: Pharmaceutical company AstraZeneca says it is buying US drug developer Alexion in a deal worth USD 39 billion. Cambridge, England-based AstraZeneca PLC, which is involved in one of the efforts to develop a COVID-19 vaccine, said Saturday it's using a combination of cash and shares for the acquisition of Boston-based Alexion Pharmaceuticals Inc.

The boards of both companies unanimously approved the transaction, which still needs regulatory and shareholder approval. The deal is expected to close in the third quarter of 2021. "This acquisition allows us to enhance our presence in immunology," AstraZeneca CEO Pascal Soriot said in a statement. Oxford-AstraZeneca Ready for ‘Mix-Match’ COVID-19 Vaccine Trial With Russia’s Sputnik V: Reports.

AstraZeneca and Oxford University have jointly developed a coronavirus vaccine that British and Canadian regulators are assessing, alongside a rival effort by US drugmaker Pfizer and Germany's BioNTech that has already earned some emergency approvals, and another by US biotechnology company Moderna.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)